The Centers for Disease Control and Prevention has a permanent director for the first time in nearly a year, after the U.S. Senate voted 51–44 on Wednesday, August 5, 2026, to confirm Dr. Erica Schwartz to lead the Atlanta-based public health agency.
The vote was largely along party lines, with Sen. Tim Kaine of Virginia reported as the only Democrat to support the nomination. Schwartz becomes President Donald Trump's third pick to run the CDC, taking the helm of an agency that has spent much of the past two years without confirmed leadership, buffeted by political conflict over vaccine policy and described in press coverage as troubled, with low morale and persistent questions about political interference in its scientific work.
Her confirmation ends a leadership vacuum that had stretched since 2025, when the previous permanent director, Dr. Susan Monarez, was fired by Health and Human Services Secretary Robert F. Kennedy Jr. following a dispute over vaccine policy. In the interim, Dr. Jay Bhattacharya — now director of the National Institutes of Health — had served as acting CDC director since February 2026.
Schwartz arrives at a moment when the agency's credibility, independence and mission are all contested terrain, and when the man who oversees it, Kennedy, has spent years publicly questioning the safety of some vaccines. How she navigates that relationship — and whether she can rebuild internal confidence at the CDC while retaining the confidence of the White House — will define her tenure.
A confirmation nearly a year in the making
The path to Schwartz's confirmation was not quick. The White House submitted her nomination to the Senate on April 21, 2026, formally opening a process that would run for more than three months.
The Senate Health, Education, Labor and Pensions (HELP) Committee held a confirmation hearing and, on July 30, 2026, voted 13–10 to advance her nomination to the full Senate. As with the final floor vote, Kaine was the only Democrat on the panel to back her.
The full Senate then confirmed her on August 5 by a margin of 51–44, a result that underscores how sharply the CDC directorship has become a partisan flashpoint. Public health agencies have historically drawn broad bipartisan support, and confirmation votes for their leaders have often been lopsided. A near party-line split over the CDC's top job reflects how thoroughly vaccine policy, pandemic-era grievances and questions about scientific independence have reshaped the politics of American public health.
Because the vote occurred in early August, Schwartz has now been in the role for roughly six weeks as of mid-September. That is enough time to have begun assembling a leadership team, engaging with career staff and signalling priorities, but not long enough for any substantial change in the agency's direction to be fully assessed.
Who is Erica Schwartz?
Schwartz enters the job with a background positioned squarely inside the public health establishment. She is described as a public health veteran who has run vaccination programs and previously served as deputy surgeon general during Trump's first administration.
That combination — prior service in a Trump administration plus a career built in conventional public health — is central to how her nomination was received. Supporters pointed to her operational experience with immunization programs and her familiarity with federal health bureaucracy. Critics, meanwhile, focused less on her résumé than on the political environment in which she will operate, and on whether any CDC director can assert scientific independence under an HHS secretary who has made vaccine skepticism a signature cause.
During the confirmation process, Schwartz repeatedly affirmed the safety and efficacy of childhood vaccines. That position was highlighted in coverage of her confirmation and is widely read as part of a broader shift in the Trump administration's tone on vaccines — a shift that followed sustained criticism of Kennedy's more contentious public statements and of the administration's handling of vaccine policy.
Whether that shift is durable or tactical is an open question. Schwartz's public affirmations of vaccine safety place her at odds with some of the constituencies that have aligned themselves with Kennedy's agenda, even as they reassure mainstream medical organizations that had grown alarmed by the direction of federal health policy.
An agency under pressure
The CDC Schwartz inherits is not the agency it was a decade ago, at least in terms of internal cohesion and external trust.
Coverage describing the situation inside the agency has characterized it as troubled, citing political interference and low morale. That assessment reflects a broader deterioration in the relationship between the CDC's career scientists and the political leadership of HHS over successive administrations — a rupture that began during the COVID-19 pandemic and has not healed.
The agency's core functions are not in question: it remains the federal government's principal instrument for disease surveillance, outbreak investigation, immunization guidance and response to infectious and non-infectious health threats. Its recommendations shape vaccination schedules, clinical practice, state health policy and global norms. When its guidance is perceived as politically motivated, the consequences ripple outward — into paediatricians' offices, state legislatures, school requirements and public willingness to follow public health advice.
The vacancy at the top compounded those problems. An agency led by an acting director is an agency whose leader has less authority, less standing in interagency fights and less ability to push back against directives from above. Schwartz's confirmation removes that particular vulnerability.
The vaccine question
No issue will define Schwartz's tenure more than vaccines.
Kennedy's tenure at HHS has been marked by sustained scrutiny of vaccine safety claims, and Monarez's dismissal in 2025 — described as the result of a dispute over vaccine policy — established that the CDC director's position on immunization is effectively a condition of employment.
Schwartz's repeated affirmations of vaccine safety and efficacy therefore carry unusual weight. They are, in effect, a public commitment made at the moment of maximum leverage, before the pressures of the job have fully applied.
Advocates of the traditional public health position have welcomed those statements. The question they now face is how much operational substance follows. Vaccine policy is not made through rhetoric alone; it runs through the Advisory Committee on Immunization Practices, through the language of official recommendations, through the timing and framing of safety communications, and through the agency's willingness to contradict political appointees when the evidence points elsewhere.
For the administration, Schwartz's appointment offers an opportunity to reset its relationship with the medical mainstream. A CDC director who is broadly acceptable to the public health community — one who affirms vaccine safety without disavowing the secretary who appointed her — allows the White House to claim that it is not, in fact, at war with established science. That is a political asset, and it explains why the confirmation was pursued even after two earlier picks fell away.
For skeptics of the administration, the same appointment is best understood as a test rather than a resolution. A director's statements during confirmation are not guarantees of what she will do when a politically charged decision lands on her desk.
Political fault lines
The 51–44 vote is itself a data point about the politics of public health in 2026.
Kaine's decision to cross party lines made him the only Democrat to support Schwartz in both the HELP Committee and on the Senate floor. That pattern suggests his support was personal and considered rather than a signal of broader Democratic willingness to back Trump-era health nominees.
Most Democratic senators voted against a nominee who had, by the standards of previous CDC confirmations, unremarkable credentials and unremarkable public positions on immunization. Their opposition is best read as a statement about the broader context: about the removal of Schwartz's predecessor, about the administration's vaccine record, about the level of political intervention in federal science, and about the belief that a nominee's individual competence cannot outweigh the structural pressures of the job.
On the Republican side, the near-unanimous support reflected both party discipline and a genuine willingness to see the administration's health agenda staffed with people it chose. Schwartz's prior service in Trump's first administration, and her professional background in vaccination programs, made her an easier vote than other nominees might have been.
The result is a director confirmed by a narrow, partisan margin — a fact she may find constraining. Directors confirmed with overwhelming bipartisan support carry an implicit mandate. Directors confirmed 51–44 do not. Schwartz will need to build authority through performance, because she was not given much of it by the Senate.
Impact and implications
Three sets of consequences follow from the confirmation.
Inside the CDC, a permanent director restores a normal chain of command. Career staff who have weathered more than a year of uncertain or acting leadership now know who is in charge, who speaks for the agency, and to whom they should escalate disagreements. Whether that stabilizes morale depends on whether Schwartz is seen to defend the agency's scientific process in disputes with HHS. A director who is perceived internally as a conduit for political direction would deepen the agency's problems rather than resolve them.
Across the federal government, Schwartz's confirmation gives HHS a CDC director with a conventional public health profile and explicit pro-vaccine statements. That affects interagency deliberations on immunization policy, pandemic preparedness, and public communication about health risks — areas where the CDC's technical authority is difficult to replace but easy to sideline if its leadership is not trusted.
For the public, the practical stakes are tangible. CDC recommendations influence what vaccines are covered by insurance, what schools require, what clinicians advise, and what state health departments prioritize. A director who affirms vaccine safety, and whose agency's guidance reflects that, supports routine childhood immunization coverage at a time when uptake has been politically contested. A director who does not would accelerate the opposite trend.
There is also an international dimension. The CDC's relationships with the World Health Organization and with counterpart agencies abroad have been strained by recent years of political turbulence, and a permanent, recognized director is a precondition for restoring routine technical cooperation.
What happens next
Schwartz's immediate tasks are organizational and communicative: filling senior positions, defining her relationship with Kennedy's office and with the White House, and signalling to the agency's career workforce how decisions will be made.
The tests will come in specific decisions rather than broad declarations. How the agency handles vaccine recommendations, how it communicates uncertainty, and whether it maintains the practice of publishing scientific findings that complicate political narratives will all be scrutinized.
There are also questions she cannot control. Kennedy remains her supervisor, and the administration's broader posture toward public health institutions remains unsettled. Another disputed vaccine decision, or another dismissal of a senior official, could reset the terms of her tenure overnight.
The bigger picture
Schwartz's confirmation is best understood as a partial stabilizer rather than a resolution. It fills an office that had been empty of confirmed leadership for nearly a year, and it places a public health veteran with an explicit pro-vaccine record in charge of an agency whose scientific authority has been seriously eroded.
That is genuinely significant. Institutions function better with accountable leadership, and the CDC's ability to respond to outbreaks — its foundational purpose — depends on having a director who can make decisions and defend them.
But the deeper tensions that produced the vacancy remain. The CDC's standing rests on the perception that its guidance follows evidence rather than politics. Rebuilding that perception requires a sustained record of decisions that are visibly independent, not a single confirmation vote.
For Schwartz, the confirmation is the beginning of an argument she will have to win continuously: that the CDC's scientific judgment can survive contact with the politics above it. The Senate has given her the job by a narrow margin. What she does with it — and how much room she is ultimately given — will determine whether the agency's long unsettled period ends, or simply enters a new phase.